- Home
- NVCT vs LXRX Comparison
NVCT vs LXRX Comparison
Compare NVCT & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVCT | LXRX |
|---|---|---|
| Founded | 2020 | 1995 |
| Country | United States | United States |
| Employees | 13 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 608.8M | 703.3M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | NVCT | LXRX |
|---|---|---|
| Price | $19.31 | $2.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $10.00 | $4.15 |
| AVG Volume (30 Days) | 525.3K | ★ 4.5M |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $49,803,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $5.55 | $1.00 |
| 52 Week High | $29.28 | $2.68 |
Technical Indicators
Market Signals| Indicator | NVCT | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.96 | 52.23 |
| Support Level | $18.02 | $2.04 |
| Resistance Level | $29.28 | $2.53 |
| Average True Range (ATR) | 1.18 | 0.14 |
| MACD | -0.31 | -0.01 |
| Stochastic Oscillator | 63.07 | 56.98 |
Price Performance
Historical ComparisonAbout NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.